Journey Medical Corporation Announces Its Phase 3 Trials Evaluating DFD-29 For Treatment Of Papulopustular Rosacea In Adults Achieved Co-Primary And All Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Journey Medical Corporation has announced that its Phase 3 trials evaluating DFD-29 for the treatment of Papulopustular Rosacea in adults have achieved co-primary and all secondary endpoints.
July 11, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Journey Medical Corporation's successful Phase 3 trials for DFD-29 could potentially boost DERM's stock in the short term.
Successful clinical trials often lead to increased investor confidence, which can drive up the stock price. As Journey Medical Corporation is likely associated with DERM, this news could have a positive impact on DERM's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100